Clinical Trial Update: Halofuginone Hydrobromide in Treating Patients With HIV-Related Kaposi's Sarcoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial of halofuginone hydrobromide for AIDS-related Kaposi sarcoma has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kaposi Sarcoma

Drugs mentioned

• Halofuginone hydrobromide (halofuginone hydrobromide)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: AIDS-related Kaposi Sarcoma, Recurrent Kaposi Sarcoma | Phase 2 | Status: COMPLETED